A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of HR19042 capsules compared to matching
placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the
treatment.